The Serum Level of Insulin Growth Factor-1 and Insulin Growth Factor Binding Protein-3 in Children with Henoch-Schönlein Purpura
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We investigated whether serum levels of insulin growth factor-1 (IGF-1) and insulin growth factor binding protein-3 (IGFBP-3) are valuable in predicting clinical outcomes or are correlated with other laboratory findings in children with Henoch-Schönlein purpura (HSP). Methods: We examined 27 children who were consecutively admitted to our hos pital with HSP between January 2011 and February 2012. Blood tests (C-reactive protein, white blood cell count, platelet count, erythrocyte sedimentation rate, albumin, immunoglobulin A, complement C3, antineutrophil cytoplasmic anti body, IGF-1, IGFBP-3) and urine tests were performed upon admission. IGF-1 and IGFBP-3 were resampled in the recovery phase. Controls included 473 children whose IGF-1 and IGFBP-3 were sampled for evaluating their growth, at the outpa tient department of pediatric endocrinology in our hospital. IGF-1 and IGFBP-3 were compared between the HSP children and controls, and between the acute and recovery phases in HSP children. The ability of these values to predict clinical outcomes including renal involvement was analyzed using bivariate logistic re gression analysis (BLRA). Results: IGF-1 and IGFBP-3 were not different between the HSP children and controls (148.7±117.6 vs. 69.2±96.9, P=0.290: 3465.9±1290.9 vs. 3597.2±1,127.6, P=0.560, respectively). There was no significant difference in IGF-1 or IGFBP-3 bet ween acute and recovery phases. Based on the BLRA, no variable, including IGF-1 and IGFBP-3, could predict clinical outcomes including the presence of nephritis Conclusion: We concluded that IGF-1 and IGFBP-3 do not predict clinical out comes of HSP, including renal involvement, in this study.
Abstract
Purpose: We investigated whether serum levels of insulin growth factor-1 (IGF-1) and insulin growth factor binding protein-3 (IGFBP-3) are valuable in predicting clinical outcomes or are correlated with other laboratory findings in children with Henoch-Schönlein purpura (HSP). Methods: We examined 27 children who were consecutively admitted to our hos pital with HSP between January 2011 and February 2012. Blood tests (C-reactive protein, white blood cell count, platelet count, erythrocyte sedimentation rate, albumin, immunoglobulin A, complement C3, antineutrophil cytoplasmic anti body, IGF-1, IGFBP-3) and urine tests were performed upon admission. IGF-1 and IGFBP-3 were resampled in the recovery phase. Controls included 473 children whose IGF-1 and IGFBP-3 were sampled for evaluating their growth, at the outpa tient department of pediatric endocrinology in our hospital. IGF-1 and IGFBP-3 were compared between the HSP children and controls, and between the acute and recovery phases in HSP children. The ability of these values to predict clinical outcomes including renal involvement was analyzed using bivariate logistic re gression analysis (BLRA). Results: IGF-1 and IGFBP-3 were not different between the HSP children and controls (148.7±117.6 vs. 69.2±96.9, P=0.290: 3465.9±1290.9 vs. 3597.2±1,127.6, P=0.560, respectively). There was no significant difference in IGF-1 or IGFBP-3 bet ween acute and recovery phases. Based on the BLRA, no variable, including IGF-1 and IGFBP-3, could predict clinical outcomes including the presence of nephritis Conclusion: We concluded that IGF-1 and IGFBP-3 do not predict clinical out comes of HSP, including renal involvement, in this study.
참고문헌 (17)
- Ronkainen J, "Outcome of Henoch-Schönlein nephritis with nephritic-range proteinuria", Clin Nephrol, 60, pp.80~84 (2003)
- Yildiz B, "Increased serum levels of insulinlike growth factor(IGF)-1 and IGF-binding protein-3 in Henoch-Schönlein purpura", Tohoku J Exp Med, 214, pp.333~340 (2008)
- Ru L, "Clinical significance of serum levels of IGF-1 and IGFBP-3 in children with Henoch-Schönlein purpura or Henoch-Schönlein purpura nephritis", Zhongguo Dang Dai Er Ke Za Zhi, 15, pp.1009~1013 (2013)
- Lin CY, "Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura", J Microbiol Immunol Infect, 39, pp.476~482 (2006)
- Ha TS, "The role of tumor necrosis factor-alpha in Henoch-Schönlein purpura", Pediatr Nephrol, 20, pp.149~153 (2005)
- Mills JA, "The American College of Theumatology 1990 criteria for the classification of Henoch-Schönlein purpura", Arthritis Rheum, 33, pp.114~121 (1990)
- Saulsbury FT, "Epidermiology of Henoch-Schönlein purpura", Cleve Clin J Med, 69, pp.187~189 (2002)
- Jauhola O, "Renal manifestations of Henoch-Schönlein purpura in a 6-month prospective study of 223 children", Arch Dis Child, 95, pp.877~882 (2010)
- Kawasaki Y, "Henoch-Schönlein purpura nephritis in childhood : pathogenesis, prognostic factors and treatment", Fukushima J Med Sci, 59, pp.15~26 (2013)
- Shin JI, "Serum IgA", C3ratio may be a useful marker of disease activity in severe Henoch-Schönlein nephritis, 2005, pp.1012, 72~78
- Balaram SK, "Insulin like growth factor-1activates nuclear factor-κB and increases transcription of the intercellular adhesion molecule-1 gene in endothelial cells", Cardiovasc Surg, 7, pp.91~97 (1999)
- Tönshoff B, "Effects of insulin-like growth factor I on the renal juxtamedullary microvasculature", Am J Physiol Renal Physiol, 274, pp.120~128 (1998)
- Rossert J, "Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy", Diabetes Metab, 26(suppl 4), pp.16~24 (2000)
- Oldroyd SD, "An IGF-I antagonist does not inhibit renal fibrosis in the rat following subtotal nephrectomy", Am J Physio Renal Physiol, 290, pp.695~702 (2006)
- Ece A, "Antioxidant enzyme activities, lipid peroxidation, and total antioxidant status in children with Henoch-Schönlein purpura", Clin Rheumatol, 27, pp.163~169 (2008)
- Chen T, "Elevated serum heme oxygenase-1 and insulin-like growth factor-1 levels in patients with Henoch-Schönlein purpura", Rheumatol Int, 31, pp.321~326 (2011)
- Ge W, "Pentraxin 3 as a novel early biomarker for the prediction of Henoch-Schönlein purpura nephritis in children", Eur J PEdiatr, 173, pp.213~218 (2014)